Advertisement
Short communication| Volume 12, ISSUE 3, P247-252, September 1986

Download started.

Ok

Immunogenetic markers in chlorpromazine-induced tardive dyskinesia

  • Rosa T. Canoso
    Correspondence
    Address reprint request to: Dr. R.T. Canoso, Hematology Section, VA Medical Center, Brockton, MA 02401, U.S.A.
    Affiliations
    Hematology Section, Medical Service and Neurology Service, VA Medical Center,Brockton /West Roxbury, USA

    Harvard Medical School, Boston, MA U.S.A.
    Search for articles by this author
  • Jorge A. Romero
    Affiliations
    Hematology Section, Medical Service and Neurology Service, VA Medical Center,Brockton /West Roxbury, USA

    Harvard Medical School, Boston, MA U.S.A.
    Search for articles by this author
  • Edmond J. Yunis
    Affiliations
    Division of Immunogenetics, Dana Farber Cancer Institute, USA

    Harvard Medical School, Boston, MA U.S.A.
    Search for articles by this author
DOI:https://doi.org/10.1016/S0165-5728(86)80008-X
Immunogenetic markers in chlorpromazine-induced tardive dyskinesia
Previous ArticleModulation of experimental allergicencephalomyelitis (EAE): Suppression of active reinduction of eae in rats recovered from passively transferred disease
      This paper is only available as a PDF. To read, Please Download here.

      Summary

      The presence and severity of tardive dyskinesia were determined in 66 patients with chronic psychiatric disorders treated with chlorpromazine. The patients were classified according to the presence of antinuclear antibodies, the lupus anticoagulant, and the HLA antigen Bw44. The severity of orofacial dyskinesia was estimated using the Rockland Research Institute Scale. Patients with autoantibodies and the Bw44 antigen had higher tardive dyskinesia scores than those with AAB without the Bw44 antigen and also patients without autoantibodies regardless of their HLA phenotype (P < 0.01). These studies suggest that the presence of autoantibodies in association with the HLA Bw44 antigen is related to, and can be a predictor of, neurological complications of long-term chlorpromazine therapy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Asherson R.A.
        • Harris E.N.
        • Gharavi A.E.
        • et al.
        Association of chorea in SLE and lupus like diseases with anti-phospholipid antibodies.
        Br. J. Haematol. 1985; 59: 227-230
        • Cannady W.G.
        • Williams R.M.
        • Yunis E.J.
        Laboratory methods in transplantation immunity.
        Prog. Clin. Pathol. 1977; 7: 239-265
        • Canoso R.T.
        • Oliveira R.M.
        Lack of thrombotic diathesis in patients with chlorpromazine-induced lupus anticoagulant and antiphospholipid antibodies.
        Blood. 1985; 66: 134a
        • Canoso R.T.
        • Oliveira R.M.
        Characterization and antigenic specificity of chlorpromazine induced antinuclear antibodies.
        J. Lab. Clin. Med. 1986; (accepted for publication)
        • Canoso R.T.
        • Sise H.S.
        Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. A prevalence study.
        Am. J. Hematol. 1982; 13: 121-129
        • Canoso R.T.
        • Hutton R.
        • Deykin D.
        Chlorpromazine induced inhibitor of blood coagulation.
        Am. J. Hematol. 1977; 2: 183-191
        • Canoso R.T.
        • Lewis M.E.
        • Yunis E.J.
        Association of HLA-Bw44 with chlorpromazine-induced autoantibodies.
        Clin. Immunol. Immunopathol. 1982; 5: 278-282
        • Creese I.
        • Burt D.R.
        • Snyder S.H.
        The dopamine receptor: differential binding of d-LSD and related agents to agonists and antagonist states.
        Life Sci. 1975; 17: 1715-1720
        • Harris E.N.
        • Gharavi A.E.
        • Boey M.L.
        • et al.
        Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.
        Lancet. 1983; ii: 1211-1214
        • Husby G.
        • Van de Rijn I.
        • Zabriskie J.B.
        Antibodies reacting with cytoplasm of subthalamic caudate nuclei neurons in chorea and acute rheumatic fever.
        J. Exp. Med. 1976; 144: 1094-1110
        • Jeste D.V.
        • Wyatt R.J.
        Understanding and Treating Tardive Dyskinesia.
        in: Gilford Press, Amsterdam1982: 10-38
        • Klawans H.
        • Barr A.
        Prevalence of spontaneous lingual facial bucal dyskinesia in the elderly.
        Neurology. 1982; 32: 558-559
        • Lusins J.D.
        • Szilagyi P.A.
        Clinical features of chorea associated with systemic lupus erythematosus.
        Medicine. 1968; 47: 337-369
        • Simpson G.M.
        • Kline N.S.
        Tardive dyskinesia and psychotropic drug history.
        Psychopharmacology. 1978; 58: 117-124
        • Spitzer R.L.
        • Endicott J.
        Research Diagnostic Criteria.
        in: Biometrics Research. 2nd edn. New York State Psychiatric Institute, New York1975
        • Strelkauskas A.G.
        • Holgram H.M.
        • Yunis E.J.
        Segre D. Smith L. Immunological Aspects of Aging. Marcel Decker, New York1981: 267-280
        • Zarrabi M.H.
        • Zucker S.
        • Miller F.
        Immunologic and coagulation disorders in chlorpromazine-treated patients.
        Ann. Int. Med. 1980; 91: 397-405

      Article info

      Publication history

      Accepted: April 21, 1986
      Received in revised form: April 21, 1986
      Received: February 6, 1986

      Footnotes

      *This work was supported by NIMH Grant No. R01 MH39528.

      Identification

      DOI: https://doi.org/10.1016/S0165-5728(86)80008-X

      Copyright

      © 1986 Elsevier Science Publishers B.V. (Biomedical Division). Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX